Literature DB >> 3689770

Structure of the major carbohydrate fragment of the Leishmania donovani lipophosphoglycan.

S J Turco1, S R Hull, P A Orlandi, S D Shepherd, S W Homans, R A Dwek, T W Rademacher.   

Abstract

The major carbohydrate fragment from the lipophosphoglycan of Leishmania donovani was generated by mild acid hydrolysis (0.02 N HCl, 5 min, 100 degrees C) and purified by chromatography on DE-52 cellulose and thin layer. By a combination of analyses including gas-liquid chromatography-mass spectrometry and 1H NMR, the structure of the fragment was elucidated as PO4----6Gal(beta 1----4)Man. Approximately 16 of these phosphorylated disaccharide units occur in the overall glycoconjugate structure. NMR analysis of an alkaline phosphatase treated phosphorylated tetrasaccharide generated from lipophosphoglycan showed that the phosphorylated disaccharide units are linked together via alpha-glycosidic linkages. Complete characterization of the phosphorylated disaccharide units of lipophosphoglycan provides the first example of a defined carbohydrate anchored in membranes by a derivative of phosphatidylinositol.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3689770     DOI: 10.1021/bi00393a042

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  25 in total

1.  Inhibition of HIV-1-mediated syncytium formation and virus replication by the lipophosphoglycan from Leishmania donovani is due to an effect on early events in the virus life cycle.

Authors:  N Genois; B Barbeau; M Olivier; M J Tremblay
Journal:  Clin Exp Immunol       Date:  2001-04       Impact factor: 4.330

2.  Inhibitory effects on protein kinase C activity by lipophosphoglycan fragments and glycosylphosphatidylinositol antigens of the protozoan parasite Leishmania.

Authors:  T B McNeely; G Rosen; M V Londner; S J Turco
Journal:  Biochem J       Date:  1989-04-15       Impact factor: 3.857

3.  Probing elongating and branching β-D-galactosyltransferase activities in Leishmania parasites by making use of synthetic phosphoglycans.

Authors:  Olga V Sizova; Andrew J Ross; Irina A Ivanova; Vladimir S Borodkin; Michael A J Ferguson; Andrei V Nikolaev
Journal:  ACS Chem Biol       Date:  2011-04-11       Impact factor: 5.100

Review 4.  Short native antimicrobial peptides and engineered ultrashort lipopeptides: similarities and differences in cell specificities and modes of action.

Authors:  Maria Luisa Mangoni; Yechiel Shai
Journal:  Cell Mol Life Sci       Date:  2011-05-15       Impact factor: 9.261

Review 5.  Biochemistry of the Leishmania species.

Authors:  R H Glew; A K Saha; S Das; A T Remaley
Journal:  Microbiol Rev       Date:  1988-12

6.  Monoclonal antibodies that recognize distinct epitopes of the macrophage type three complement receptor differ in their ability to inhibit binding of Leishmania promastigotes harvested at different phases of their growth cycle.

Authors:  A Cooper; H Rosen; J M Blackwell
Journal:  Immunology       Date:  1988-12       Impact factor: 7.397

7.  Mechanisms of immune evasion in leishmaniasis.

Authors:  Gaurav Gupta; Steve Oghumu; Abhay R Satoskar
Journal:  Adv Appl Microbiol       Date:  2013       Impact factor: 5.086

8.  The role of phosphoglycans in Leishmania-sand fly interactions.

Authors:  D L Sacks; G Modi; E Rowton; G Späth; L Epstein; S J Turco; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  2000-01-04       Impact factor: 11.205

9.  Lipophosphoglycan from Leishmania suppresses agonist-induced interleukin 1 beta gene expression in human monocytes via a unique promoter sequence.

Authors:  D E Hatzigeorgiou; J Geng; B Zhu; Y Zhang; K Liu; W N Rom; M J Fenton; S J Turco; J L Ho
Journal:  Proc Natl Acad Sci U S A       Date:  1996-12-10       Impact factor: 11.205

10.  Structural characterization of a novel glycosyl-phosphatidylinositol from the protozoan Tetrahymena mimbres.

Authors:  U Weinhart; J R Thomas; Y B Pak; G A Thompson; M A Ferguson
Journal:  Biochem J       Date:  1991-10-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.